New Zealand markets closed
  • NZX 50

    11,267.39
    +60.46 (+0.54%)
     
  • NZD/USD

    0.6410
    +0.0027 (+0.43%)
     
  • NZD/EUR

    0.6062
    +0.0037 (+0.62%)
     
  • ALL ORDS

    7,391.00
    +87.70 (+1.20%)
     
  • ASX 200

    7,145.60
    +81.10 (+1.15%)
     
  • OIL

    110.35
    +0.46 (+0.42%)
     
  • GOLD

    1,845.10
    +3.90 (+0.21%)
     
  • NASDAQ

    11,835.62
    -40.01 (-0.34%)
     
  • FTSE

    7,389.98
    +87.24 (+1.19%)
     
  • Dow Jones

    31,261.90
    +8.77 (+0.03%)
     
  • DAX

    13,981.91
    +99.61 (+0.72%)
     
  • Hang Seng

    20,717.24
    +596.56 (+2.96%)
     
  • NIKKEI 225

    26,739.03
    +336.19 (+1.27%)
     
  • NZD/JPY

    81.9320
    +0.4160 (+0.51%)
     

3 Clinical Trials to Watch in the First Half of 2022

·3-min read

In this Motley Fool Live video recorded on Jan. 12, 2022, Fool contributors Keith Speights and Brian Orelli discuss three clinical trials especially worth watching in the first half of 2022. Which clinical results are you especially looking forward to seeing? Brian Orelli: Arena (NASDAQ: ARNA), the ticker there is A-R-N-A, it expects data from a phase 3 study of etrasimod in patients with ulcerative colitis.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting